Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2023 07:00 ET | Source: AC Immune SA

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response...
November 23, 2022 07:30 ET | Source: AC Immune SA

AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...
October 19, 2020 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

Pittsburgh, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
May 22, 2018 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
November 08, 2017 08:12 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Pittsburgh, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
August 23, 2017 09:45 ET | Source: Cognition Therapeutics, Inc.

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
April 03, 2017 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference

Pittsburgh, April 03, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...